Stocksigma LogoStocksigma Logo

Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report

CRISIL Ratings issued its final monitoring agency report for Akums Drugs and Pharmaceuticals Ltd. for the quarter ended 30th Sep'26, confirming 100%

Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report

Akums Drugs and Pharmaceuticals Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 7:54 pm

Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report CRISIL Ratings issued its final monitoring agency report for Akums Drugs and Pharmaceuticals Ltd. for the quarter ended 30th Sep'26, confirming 100% utilization of its Rs 6,800.00 mn gross IPO proceeds (revised net proceeds of Rs 6,421.80 mn). Key deployments include Rs 3,870.00 mn toward debt repayment for the company and subsidiaries, Rs 550.00 mn for incremental working capital, Rs 301.80 mn for inorganic acquisitions, and Rs 1,700.00 mn for general corporate purposes. With zero unutilized proceeds remaining, future quarterly monitoring submissions are no longer required.

Original exchange filing (PDF)

More announcements from Akums Drugs and Pharmaceuticals Ltd

All Akums Drugs and Pharmaceuticals Ltd announcements